Empagliflozin + Linagliptin in pharma franchise in Tamil Nadu

Name: Emplozin L 25/5 Tablet (Empagliflozin 25mg + Linagliptin 5mg)
Brand: Emplozin L 25 5 Tablet
Rating: 4.8 (150 reviews)

Empagliflozin + Linagliptin in PCD pharma franchise in Panaji

Empagliflozin + Linagliptin in top pharma company in Patna

Empagliflozin + Linagliptin in pcd pharma supplier in Vadodara

Empagliflozin + Linagliptin in phama franchise company in India

Empagliflozin + Linagliptin in phama distributor in Ghaziabad

Home/Products /empagliflozin-25mg-linagliptin-5mg-tablet

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Empagliflozin + Linagliptin Tablet at the best price in Pharma Export Companies for SGLT2 Inhibitor, Type 2 Diabetes Management.

Empagliflozin + Linagliptin Tablet at the best price in Pharma Top Company for SGLT2 Inhibitor, Type 2 Diabetes Management.

Empagliflozin 25mg + Linagliptin 5mg Tablet – PCD Pharma Franchise Marketing Material

Emplozin L 25/5 Tablet at the best price in Antidiabetic Pharma Franchise.

Empagliflozin 25mg linagliptin 5mg anti-diabetic combination oral tablet product literature PDF

Emplozin L 25 5 Tablet

Composition : Empagliflozin (25mg) + Linagliptin (5mg)

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹345/-

Contact For Business Query

Emplozin L 25/5 Tablet is a fixed-dose combination of Empagliflozin (25mg) and Linagliptin (5mg), specifically designed for the effective management of type 2 diabetes mellitus. This dual-action therapy combines an SGLT2 inhibitor and a DPP-4 inhibitor to help control blood glucose levels, address common complications, and improve overall metabolic control.

Empagliflozin helps lower blood glucose by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, preventing glucose reabsorption and promoting its excretion through urine. This reduces blood sugar levels, aids weight loss, and can also reduce the risk of cardiovascular complications.
Linagliptin works by inhibiting the enzyme DPP-4, which breaks down incretin hormones responsible for stimulating insulin release. This helps to regulate blood glucose, particularly after meals, without significant risk of hypoglycemia.

By targeting different mechanisms, Emplozin L 25/5 Tablet provides comprehensive diabetes management, supporting better blood sugar control and enhancing overall patient outcomes.

About the Product

Empagliflozin helps lower blood glucose by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, preventing glucose reabsorption and promoting its excretion through urine. This reduces blood sugar levels, aids weight loss, and can also reduce the risk of cardiovascular complications.
Linagliptin works by inhibiting the enzyme DPP-4, which breaks down incretin hormones responsible for stimulating insulin release. This helps to regulate blood glucose, particularly after meals, without significant risk of hypoglycemia.

By targeting different mechanisms, Emplozin L 25/5 Tablet provides comprehensive diabetes management, supporting better blood sugar control and enhancing overall patient outcomes.

Common side effects include upper respiratory tract infections, headache, nausea, and urinary tract infections. Serious side effects may involve kidney problems, hypotension, and dehydration.

Emplozin L 25/5 Tablet is indicated for type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, particularly in patients inadequately controlled on other oral anti-diabetic therapies.

Consult your healthcare provider if you have a history of kidney disease or heart conditions before using this medication. Not recommended during pregnancy or breastfeeding.

Store at room temperature (15°C-30°C) in a dry place, away from light and moisture.